← Back

Wire · opportunities

Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results

Published

10 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

Protalix BioTherapeutics reported increased revenues and net income for Q3 2026, expects to meet or exceed full-year 2026 revenue guidance, and continues advancement of PRX-115 for uncontrolled gout with Phase 2 top-line results expected in H2 2027. Elfabrio for Fabry disease received marketing authorization in Brazil, and the company is focusing on rare renal disease preclinical programs.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your rare disease biotech has clear commercial momentum with rising revenue and cash strength driving clinical progress. Now is the moment to prepare for 2027 PRX-115 data that could reshape gout treatments if positive.

◆ Coverage

1 source · 10 Nov 2026

◆ Related on Wire

◆ Topics

Biotechbiotechrare-diseasesclinical-trialsfinancial-resultsdrug-development